Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension
← catalyst calendarNCT06282549 · readout in 224 d
Sponsored by Yuhan Corporation (industry) · 000100.KS — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,219actual
Sites
5
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-08 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Essential Hypertension
Intervention
- Drug: Telmisartan/Amlodipine/Chlorthalidone(Truset)
Primary outcome
what the primary-completion date above is the date OFPercentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events)
measured 12, 24 and 36months
Permalink · 000100.KS's whole pipeline · Catalyst calendar · Every registered study · What changed